Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated schistosomiasis control strategies downstream of the Three Gorges Dam
ACTRN12611000193976Phase 3Active, not recruiting
- Sponsor
- QIMR Berghofer Medical Research Institute
- Start
- Dec 2010
- Modality
- Small Molecules, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of praziquantel, niclosamide, SjCTPI-Hsp70/IL-12 DNA vaccine and pVAX plasmid DNA in schistosomiasis (6 arms), sponsored by QIMR Berghofer Medical Research Institute. Primary endpoint: Human schistosomiasis incidence. Started Dec 2010; status: active, not recruiting.
02
Drugs
praziquantelniclosamideSjCTPI-Hsp70/IL-12 DNA vaccinepVAX plasmid DNA
03
Conditions
schistosomiasis
Beyond the preview
Go deeper on ACTRN12611000193976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000193976.